Prenzler analyst coverage

Prenzler is a full-service broker in WA and this report was written without us paying, so its independence is valuable.

Better still the analyst has done a very good job so I recommend the read.

The report provides an overview of Arovella's progress and outlines why the upcoming first patient dosing study represents a significant milestone for the Company.

Arovella recently had two significant achievements: first the release of the first clinical batch of ALA-101 this should not be underestimated as producing cells for an off the shelf product is potentially a game changer for patient access and care. The second, activation of The Alfred hospital as the first clinical trial site and there are others in the pipeline. These achievements mean screening and enrolment activities are underway, with first patient dosing expected within weeks.

The report highlights that the transition from preclinical development to patient treatment is pivotal in demonstrating the potential of our CAR-iNKT platform and discusses the broader opportunity for off-the-shelf cell therapies and the growing global interest in next-generation CAR-T technologies. It notes that Arovella's approach is differentiated through its use of invariant natural killer T (iNKT) cells and outlines how data generated from ALA-101 could support expansion into autoimmune disease and solid tumours.

Importantly, the report identifies several upcoming catalysts that shareholders should watch in coming months, including first patient dosing, activation of additional clinical sites across Australia and New Zealand, early safety observations, B-cell depletion data, and progress with the ALA-105 solid tumour program. This promises to be a very interesting spectator sport over the coming months.

I encourage you to read the full note for additional context and independent commentary on our progress as we move toward becoming an active clinical-stage company.

Can I also encourage you to look at the Prenzler site www.prenzlergroup.com.au and register and get on their mailing list as I have done.

Regards,

David Williams
Chairman

View analyst report: Arovella Therapeutics (ASX: ALA) – Arovella Nears First Patient Dosing with ALA-101